Recent Quotes (30 days)

You have no recent quotes
chg | %

Stellar Biotechnologies Inc  

(Public, CVE:KLH)   Watch this stock  
Find more results for KLH
- Close
CVE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 3.88 - 14.33
Open     -
Vol / Avg. 0.00/5,576.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.44
Shares 8.45M
Beta     -
Inst. own     -
Feb. 5, 2018
Q1 2018 Stellar Biotechnologies Inc Earnings Release (Estimated) - 4:00p.m. EST - Add to calendar
Dec. 1, 2017
Q4 2017 Stellar Biotechnologies Inc Earnings Release

Key stats and ratios

Q4 (Dec. '15) 2015
Net profit margin -333.87% -374.73%
Operating margin -267.81% -571.85%
EBITD margin - -550.83%
Return on average assets -63.04% -22.87%
Return on average equity -74.13% -36.20%
Employees 23 -
CDP Score - -


332 E Scott St
PORT HUENEME, CA 93041-2939
United States - Map
+1-805-4882800 (Phone)
+1-805-4882889 (Fax)

Website links


Stellar Biotechnologies, Inc. is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH). KLH is an immune-stimulating protein. KLH can be used as an active pharmaceutical ingredient (API) and combined with a disease-targeting agent to create immunotherapies for the treatment of a range of diseases. The Company's core business is developing and commercializing Keyhole Limpet Hemocyanin for use in immunotherapy and immunodiagnostic applications. The Company's Stellar KLH product offerings include Stellar KLH protein for conjugation and as carrier molecule in immunotherapy development; Stellar KLH protein and enzyme-linked immunosorbent assay (ELISA) test kits for immune function testing, and Custom KLH formulations, adjuvants, conjugations and fill finishes for preclinical research and drug development applications.